A 30 Day Acute Efficacy and Safety Study of Chromium Picolinate + Biotin on Glycemic Control in Overweight or Obese Subjects With T2DM

Diabetes Mellitus, Type 2 Clinical Trial

Official title:

”A Randomized, Double Blinded, Placebo Controlled, Parallel Arm, Study to Evaluate the Improvement in Glycemic Control After Daily Administration of Chromium Picolinate and Biotin in Patients With Type 2 Diabetes Mellitus”

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00308451
• Other study ID #: N21 CPB-03001
• Status: Completed
• Phase: N/A
• First received: March 27, 2006
• Last updated: March 27, 2006
• Start date: November 2003
• Est. completion date: April 2004

Study information

• Verified date: March 2006
• Source: Nutrition 21, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: US FDA (DSHEA)United States: New England IRB
• Study type: Interventional

Clinical Trial Summary

The purpose of the proposed work is to assess the effects of a dietary supplement, containing chromium (600 mcg per day) provided by chromium picolinate and biotin (2 mg per day) on glycemic control in type 2 diabetes. Specifically, this study will assess whether use of the supplement will lower the post-prandial rise in blood glucose experienced after ingestion of a 75g carbohydrate load, relative to placebo, in type 2 diabetic patients. The study will also assess the chronic effects of supplementation over a 4-week period (relative to placebo) on fasting plasma levels of glucose, insulin, lipids and lipoproteins.

Description:

The purpose of this work is to assess the effects of a dietary supplement, containing chromium (600 mcg per day) provided by chromium picolinate and biotin (2 mg per day) on glycemic control in type 2 diabetes who are currently taking an oral antidiabetic agent (OAD) and failing therapy with OADs. Subjects entering the trial must have a HbA1c >/= 7.0% and have an OGTT >/= 200 mg/dL at 2 hours post consumption of a 75 g glucose beverage. The study is an acute 30 day intervention in conjunction with the subject's current OADs and standard of care in comparison to placebo.

Specifically, this study will assess whether use of the supplement will lower the post-prandial rise in blood glucose experienced after ingestion of a 75g carbohydrate load, relative to placebo, in type 2 diabetic patients as measured by the area under the curve for glucose (AUCg). The study will also assess the acute effects of supplementation over a 4-week period (relative to placebo) on fasting plasma levels of glucose, fructosamine, insulin, lipids and lipoproteins.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: April 2004
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Diagnosis of type 2 diabetes > 12 months.

2. Post-prandial blood glucose (glucose > 200 mg/dl) levels consistent with an ADA diagnosis of diabetes as confirmed during the screening visit.

3. Male and female between the ages of 18 and 65 years.

4. HbA1c > 7.0%.

5. Use of treatment regimens including diet and exercise and/or drug therapy for diabetes are allowed. Drug therapy may include alpha-glucosidase inhibitors (e.g. acarbose, voglibose, miglitol) and oral hypoglycemic agents such as sulfonylureas and metformin and thiazolidinediones (TZDs). Insulin use is not allowable

6. No changes in medication dosage within 60 days prior to entering trial.

7. Subjects with a body mass index (BMI) >25 and < 35.

8. Fasting triglycerides < 400. [32]

9. Willing to complete all study related requirements.

10. Subject will provide written consent to participate in the trial and this consent must be given voluntarily.

Exclusion Criteria:

1. Diagnosis of type I diabetes.

2. Hypoglycemic event requiring EMS intervention < 12 months.

3. Diabetic Ketoacidosis (DKA) < 12 months.

4. Subjects taking any supplement containing chromium within the previous 90 days prior toenrollment.

5. Creatinine > 2.0 x ULN; AST or ALT > 2.0 x ULN; Total Bilirubin > 1.5 x ULN.

6. COPD, CHF, Angina, HTN, MI, or any other CVD requiring hospitalization within the previous 12 months.

7. History of cerebrovascular accident (CVA), pulmonary embolism (PE), or an unresolved deep vein thrombosis (DVT).

8. History of CABG, PTCA, or any other reperfusion therapy < 12 months.

9. Uncontrolled high blood pressure (seated: systolic > 160 mmHg or diastolic > 90 mmHg)

10. History of any serious immunosuppressive disorder or undergoing current immunosuppressive therapy.

11. Female subjects who are pregnant or nursing, or are planning on becoming pregnant during the study. No hormone replacement therapy for post-menopausal subjects.

12. Hepatic disease, impaired thyroid, or impaired renal function, or other diseases known to affect glucose or lipid metabolism. TSH must be within range of normality to enter trial.

13. Diagnosed or self-reported alcoholism or substance-abuse problems

14. Any psychiatric or mental health issue that would prevent the subject from completing the study

15. Any illness or complication factor that, in the opinion of the investigator, would jeopardize the subject’s health or well being by participating in the study or would interfere with the subject successfully completing the study.

16. Current participation in any other clinical research trial for any product or device, or participation in said clinical trials within 30 days prior to enrollment.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2

Intervention

Drug:
• Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg)

Locations

Country	Name	City	State
United States	Radiant Research Chicago	Chicago	Illinois

Sponsors (1)

Lead Sponsor	Collaborator
Nutrition 21, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary(baseline versus final): AUCg as recorded from a 2-hour OGTT with 75 g glucose beverage; fructosamine; fasting plasma glucose.
Secondary	Secondary (baseline versus final): Lipid panels (Total-C, HDL, LDL, VLDL), lipid ratios , apolipoprotein A and B.